APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.  

In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage.

APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda Pharmaceutical Development Services.   Working together as a virtual project team, APTrans acts as a one-stop-shop for the core technical disciplines needed for successful drug discovery and development.

Dr Stephen Franklin, Founder and CEO of Evgen Pharma, said: “We are delighted to have found a flexible way to access specialist technical expertise and operational support to complement our existing internal capabilities to support the ongoing development of our lead product, SFX-01.  We selected this excellent group of providers as our partners as they have a proven track record of working well together and they are all co-located at the Biohub where we too have a presence.”

Ned Wakeman, Director, Biohub at Alderley Park, commented: “The APTrans initiative is a tangible example of how the environment here can accelerate business value.  The companies within APTrans all spun out from AstraZeneca, participated in business acceleration programmes, and are thriving in their own right.  We are passionate about nurturing an open and collaborative environment where like-minded companies can work, socialise and support each other, and are proud to share in the combined successes of these great companies.”

Read more here

By |2018-07-11T16:56:25+00:00March 8th, 2017|Press|Comments Off on APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.  

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.